Coleman et al. / MSKCC developed a vascular-targeted therapy for bladder cancer. Padeliporfin is illuminated with the Modulight’s ML7710 laser, resulting in selective ablation of bladder tumors, without harming the healthy bladder tissue.
Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Read More »
A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.
Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »
Kobayashi et al. at NIH developed a therapy which results in tumor cell membrane destruction and immunogenic cell death. When activated with the ML7710 laser, there was proven efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer.
Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 Read More »
Timothy C. Zhu et al. at University of Pennsylvania investigated the use of PDT for mesothelioma, an aggressive lung cancer. 24 malignant pleural mesothelioma patients were treated with photodynamic therapy using Photofrin and the ML7710 laser.
Modulight Spotlights: LASER-SHARP RESEARCH – December 2024 Read More »
Only 1 in 10 patients qualify for surgical resection of the pulmonary metastases – thus the management remains a significant clinical challenge. K. Ramadan et al. studied PDT and demonstrated the feasibility and safety of the procedure using 5-ALA and Chlorin e6 drugs with Modulight’s ML6600 laser.
Modulight Spotlights: LASER-SHARP RESEARCH – November 2024 Read More »
Modulight Spotlights: LASER-SHARP RESEARCH – October 2024 Read More »
University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients.
Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 Read More »
New findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Using ML7710 laser at 672 nm for activation of the drug, they were able to dramatically improve therapeutic effect in prostate cancer models.
Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Read More »
A promising new therapy against viruses was developed at University of Manitoba and Theralase Technologies. The study evaluated antiviral effectiveness of a cancer drug (Ruvidar), activated with Modulight’s ML6600 green laser.
Modulight Spotlights: LASER-SHARP RESEARCH – June 2024 Read More »
